Introduction {#sec1_1}
============

*Clostridium difficile* was discovered in the stool in 1935 by Hall and O\'Toole \[[@B1]\], but it was not until approximately 43 years later when in 1978 George et al. \[[@B2]\] and Bartlett et al. \[[@B3]\] discovered that *C. difficile* was the organism responsible for most of the cases of antibiotic-associated diarrhea. *C. difficile* was estimated to cause almost half a million infections in the United States in 2011. Approximately 29,000 died within 30 days of the initial diagnosis \[[@B4]\]. *C. difficile* is a spore-forming, Gram-positive anaerobic bacillus that produces two exotoxins: toxin A and toxin B. It is a common cause of antibiotic-associated diarrhea. It accounts for 15--25% of all episodes of antibiotic-associated diarrhea \[[@B4]\]. Risk factors associated with transmission are antibiotic exposure, gastrointestinal surgery/manipulation, a long length of stay in healthcare settings, a serious underlying illness, immunocompromising conditions, and advanced age \[[@B4]\]. Extraintestinal manifestations of CDI especially empyema are rare. Smith and King \[[@B5]\] were one of the first to describe extracolonic CDI. They reported on 2 cases of empyema caused by CDI. Methods of inoculation are usually that of aspiration, although some had described external contamination through chest tubes \[[@B5], [@B6], [@B7], [@B8]\]. To our knowledge, only 6 previous cases of CDI causing empyema were described, ours being the seventh.

Case Report {#sec1_2}
===========

A 42-year-old Hispanic male presented to our hospital with worsening shortness of breath of 3 weeks\' duration, cough with green color sputum, subjective fevers, decreased PO intake, and as per the patient a 40-pound weight loss. His weight documented on previous admission was approximately 175 pounds, and upon the current admission the patient weight approximately 158 pounds amounting to a weight loss of 9.71% in approximately 2 months. Four months prior to this presentation, the patient was admitted to our hospital with similar complaints and he was diagnosed with *Klebsiella pneumoniae* with parapneumonic effusion. The patient was given antibiotics and thoracentesis was done. Pleural fluid analysis is shown in Table [1](#T1){ref-type="table"}. His past medical history including liver cirrhosis secondary to NAFLD, hypothyroidism, and morbid obesity for which he had undergone Roux-en-Y gastric bypass 7 years prior to the current presentation. He also developed achalasia, 6 years after gastric bypass surgery for which he got Botox injection with symptomatic improvement. His initial labs were essentially benign, physical exam was normal except for diminished lung sounds in the right lower and right middle lobes. Computed tomography of the chest was done which was consistent with a thick-walled fluid collection at the right lower chest cavity containing fluid and air, suspicious for empyema (Fig. [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). The patient was admitted to the general medical floors and started on meropenem and linezolid. A 14-Fr pigtail catheter was inserted in pleural cavity with removal of approximately 200 cm^3^ of thick purulent pleural fluid. The fluid was sent for evaluation including cytology which was suggestive of empyema (Table [1](#T1){ref-type="table"}). Due to decreased drainage of the pleural fluid through the catheter which was likely secondary to loculations and worsening of patient\'s respiratory status, surgery was consulted for video-assisted thoracoscopic surgery (VATS). The patient underwent VATS which showed extensive empyema with numerous adhesions and a thickened pleural peel. The patient underwent extensive lysis of adhesions, and right lower lobe wedge resection, and insertion of two 32-Fr chest tubes for continued drainage. During the VATS procedure, the pleural fluid was sent for analysis including anaerobic and aerobic Gram culture and stain which was positive for *C. difficile*. Intravenous metronidazole was started. The patient had no history of CDI, and blood cultures were negative for *C. difficile* but were positive for *K. pneumoniae*. A stool *C. difficile* toxin assay was sent which returned negative for toxin, antigen, and PCR testing. The chest tubes were removed and the patient recovered well.

Discussion {#sec1_3}
==========

Extra-intestinal manifestations of CDI are rare. In 2013, Mattila et al. \[[@B9]\] conducted a retrospective study of extraintestinal CDIs during a 10-year period. Extraintestinal CDI was found in 31 patients who comprised 0.17% of all CDIs \[[@B9]\]. Two patients had bacteremic infections, 4 had abdominal infections without any prior surgery, 7 had abdominal infections after surgery, 4 had perianal abscesses, 13 had wound infections, and 1 had *C. difficile* in a urinary catheter \[[@B9]\]. García-Lechuz et al. \[[@B10]\] reported 17 cases of extracolonic *C. difficile* from a single institution over a 10-year period. Peritonitis, intra-abdominal abscess, or abdominal wound infection were identified in 13 of the 17 cases. Additionally, brain abscess, chronic osteomyelitis, and pyelonephritis were each reported \[[@B10]\].

Smith and King \[[@B5]\] were among the first to describe extracolonic CDI (Table [2](#T2){ref-type="table"}). They described 2 cases of empyema caused by CDI; the first case was a 65-year-old man who had suffered from chronic pleuritis where CDI was isolated on two separate occasions. The second case was a 58-year-old male with a pneumothorax and subsequent pleural effusion. In both cases, the infections were likely secondary to aspiration \[[@B5]\]. Simpson et al. \[[@B6]\] also reported one case of CDI in empyema. In that case, the proposed method of infection was a chest tube into a pre-existing empyema. Unfortunately, no stool samples were sent for culture. The only other mechanism through which the pleural fluid could be contaminated is hematogenous spread. However, in a review by Feldman et al. \[[@B11]\], no cases of *C. difficile* bacteremia resulted in pneumonia or empyema.

It is important to report that most cases of extraintestinal CDI were polymicrobial in nature, Spagnuolo and Payne \[[@B12]\] showed that *Clostridium perfringens* is more likely to infect the pleural cavity as a pure culture with no other microbial infection. Marina et al. \[[@B13]\] reported on anaerobic pleuropulmonary infections and found that of 116 organisms isolated, only two were *C. difficile* and only one of these was a pure culture.

The precise mechanism of *C. difficile* empyema in our patient is unclear. Possible risk factors were prolonged hospital stay and broad-spectrum antibiotics. Given his history of achalasia, it is possible he could have aspirated resulting in pulmonary infection. In addition, he had undergone a prior thoracentesis which could have caused contamination of pleural space. Interestingly, he had never been infected with *C. difficile* on the current or prior admission. His stool toxin assay was negative and blood cultures sent on two separate occasions remained negative.
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###### 

Pleural fluid analysis

  Date                   Pleural fluid analysis of previous thoracentesis   Pleural fluid analysis of current thoracentesis
  ---------------------- -------------------------------------------------- -------------------------------------------------
  Appearance             Cloudy                                             Turbid
  Color                  Orange                                             Orange
  Fluid RBC              8,730                                              23,200
  Fluid WBC              2,295                                              166,400
  Fluid PMN, %           1                                                  91
  Fluid lymph, %         66                                                 1
  Fluid monocytes, %     12                                                 8
  Fluid eosinophils, %   18                                                 0
  Fluid histiocytes, %   3                                                  0
  Glucose fluid          106                                                --
  Total protein fluid    4.2                                                4.4
  LDH fluid              194                                                7,337
  Cholesterol fluid      57                                                 46
  Triglyceride fluid     21                                                 20
  ADA                    Neg                                                --
  Albumin fluid          1.8                                                1.1
  Albumin serum          2.4                                                1.5
  LDH serum              124                                                104

First column from the initial thoracocentesis and second column from subsequent pleural fluid analysis.

###### 

Previously reported cases of *C. difficile* empyema

  Ref.   Sex/age   Predisposing condition   Stool                                 Outcome        Other organism isolated   Possible transmission
  ------ --------- ------------------------ ------------------------------------- -------------- ------------------------- -----------------------------------------
  5      65/M      Pleurisy                 Not Recorded                          Not recorded   None                      Aspiration
                                                                                                                           
  5      58/M      Pneumothorax             Not Recorded                          Not recorded   None                      Aspiration
                                                                                                                           
  14     52/F      Pleural effusion         Not Recorded                          Improved       None                      Aspiration
                                                                                                                           
  7      65/M      Pleural effusion         Negative/+history of *C. difficile*   Improved       None                      Aspiration
                                                                                                                           
  8      53/M      Pleural effusion         Negative                              Improved       None                      Aspiration
                                                                                                                           
  6      46/M      Pleural effusion         Negative                              Improved       None                      Contamination from chest tube insertion
